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Chronic pain is a debilitating condition with major socioeconomic impact, whose neurobiological basis is still not clear. An
involvement of the neurovascular unit (NVU) has been recently proposed. In particular, the blood-brain barrier (BBB) and blood-
spinal cord barrier (BSCB), two NVU key players, may be affected during the development of chronic pain; in particular, transient
permeabilization of the barrier is suggested by several inflammatory- and nerve-injury-based pain models, and we argue that
the clarification of molecular BBB/BSCB permeabilization events will shed new light in understanding chronic pain mechanisms.
Possible biases in experiments supporting this theory and its translational potentials are discussed. Moving beyond an exclusive
focus on the role of the endothelium, we propose that our understanding of the mechanisms subserving chronic pain will benefit
from the extension of research efforts to theNVUas awhole. In this view, the available evidence on the interaction between analgesic
drugs and the NVU is here reviewed. Chronic pain comorbidities, such as neuroinflammatory and neurodegenerative diseases, are
also discussed in view of NVU changes, together with innovative pharmacological solutions targeting NVU components in chronic
pain treatment.
1. Introduction
According to the International Association for the Study of
Pain (IASP), pain is an unpleasant sensory and emotional
experience associated with actual or potential tissue damage,
or described in terms of such damage [1].
Chronic pain onset can be sudden or slow and progres-
sive, varies in intensity frommild to severe, and its end cannot
be predicted. The diagnosis of chronic pain requires that the
condition lasts longer than 3–6months. Chronic pain can be a
debilitating condition with potentially devastating impact on
the quality of life [2]. It occurs in a wide variety of conditions,
including peripheral neuropathy, stump pain, phantom pain,
complex regional pain syndrome, central pain, polymyalgia
rheumatica, fibromyalgia, pain of psychological origin, and
epilepsy. The recently revised taxonomy includes several
new conditions, such as chronic paroxysmal hemicrania:
remitting form, hemicrania continua, postlumbar puncture
headache, and so forth [1].
According to a report released in June 2011 by the Institute
of Medicine of the National Academies, chronic pain affects
about 100 million American adults—more than the total
affected by heart disease, cancer, and diabetes combined [3].
The 2010 Patient Protection andAffordable Care Act required
the Department of Health and Human Services of the United
States of America to consider pain as a public health problem.
A 2006 study in 15 European countries and Israel indi-
cates that chronic pain of moderate to severe intensity occurs
in 19% of adult Europeans, seriously affecting the quality of
their social and working lives [4]. A more recent evaluation
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of chronic pain in the EuropeanUnion reports an even higher
impact on the general adult population, with an average
prevalence of 27%, similar to the that of other common
chronic conditions [5].
Understanding the biological, cognitive, and psychologi-
cal underpinnings of chronic pain represents amajor research
challenge. From a neurobiological standpoint, the cellular
and molecular communication between the central nervous
system (CNS) parenchyma and the circulating mediators of
the immune and inflammatory response is at the core of
such challenge. Indeed, an increasingly compelling body of
evidence highlights a major role for the role of nonneuronal
cells and diffusible mediators in the functional state of the
brain, including neuronal excitability.The concept is captured
in the term “neurovascular unit” (NVU), an ensemble of
cellular and noncellular players (neurons, endothelial cells,
glial cells, pericytes, the extracellular matrix, immune cells,
inflammatory mediators) which form an integrated func-
tional unit [6, 7].
In the context of the NVU, an obviously crucial role is
played by the blood-brain barrier (BBB) and of the blood-
spinal cord barrier (BSCB), both in general and with respect
to the pathophysiology of chronic pain.
The purpose of this review is to explore the role played
in the establishment and maintenance of chronic pain by the
NVU, emphasizing (but not limited to) BBB and/or BSCB
permeabilization phenomena. Chronic pain has a significant
prevalence in neurodegenerative and neuroinflammatory
pathologies, and BBB/BSCB permeabilization is discussed in
this extended context. Finally, novel strategies targeting the
NVU are considered for chronic pain relief.
2. BBB and BSCB in the Neurovascular Unit
The importance of a full understanding of BBB/BSCB func-
tion is emphasized by its well-known role in regulating
paracellular and transcellular drug transport, thus preventing
or allowing CNS-acting drugs for chronic pain relief to reach
their intended target [8]. In addition, there is a possibility that
BBB/BSCB permeability may be altered in association with
the development of chronic pain [9–12].
2.1. Anatomical Structure of Blood-Brain Barrier and Blood-
Spinal Cord Barrier. The BBB is the regulating interface
between circulating blood and brain parenchyma. Endothe-
lial cells of brain capillaries, unlike those of the periph-
eral circulation, are characterized by the absence of cell
membrane fenestrations, the presence of tight junctions,
having a high number of cytosolic mitochondria, and min-
imal pinocytotic activity [7]. As an exception, the so-called
circumventricular organs (CVOs) do possess fenestrated
vasculature. In particular, secretory CVOs (median eminence
and neurohypophysis) present a higher vascular permeability
for low-molecular-mass tracers compared to sensory CVOs
(organum vasculosum of lamina terminalis, subfornical
organ, and area postrema) [13].
The surface area of the BBB, depending on the anatomical
region, is between 150 and 200 cm2/g of tissue, resulting in a
total area for blood-brain exchange between 12 and 18m2 for
the average human adult [14].
A functional equivalent of the BBB is the blood-spinal
cord barrier (BSCB), constituted by nonfenestrated endothe-
lial cells, basement membrane, pericytes, and astrocytic feet
processes [15]. Several aspects distinguish BSCB from BBB,
such as the glycogen deposits in the superficial vessels of
the spinal cord [16], increased permeability to tracers and
cytokines [17–19], decreased expression of tight-junction pro-
teins and adherens junction proteins [20]. Such differences
should be taken into account when these barriers are targeted
for chronic pain treatment.
2.2. Mechanisms of Transport through Blood-Brain Barrier.
The BBB has low passive permeability to many essential
water soluble nutrients and metabolites required by the
nervous tissue. However, in healthy conditions, the BBB
shows temporary increases in permeability, allowing access
to nutrients and oxygen. Since no brain cell is farther than
about 15𝜇m from a capillary [21], drugs and other solutes
can rapidly reach all neurons and glial cell bodies, once the
BBB has been crossed. Exchange of small organic compounds
between blood and brain is regulated by plasma membrane
transporters working either in the blood-to-brain direction,
the brain-to-blood direction, or both. The directionality of
transport is set by the subcellular location of the trans-
port system (blood-facing or brain-facing membrane of the
endothelial cells) and by the transportmechanism [8]. Several
transport pathways have been identified in the BBB, such
as (i) passive diffusion into brain of lipid soluble molecules
(e.g., oxygen and carbon dioxide); (ii) ATP-binding cas-
sette transporters (ABC-transporter, see below) efflux (P-
glycoprotein (P-gp), multidrug resistance protein (MRP) 1–
6, and breast cancer resistance protein transporters (BCRP));
(iii) solute carriers—SLC (transporters of glucose, amino
acids, nucleosides, monocarboxylic acids, thyroid hormone,
organic anions, organic cations, amine, and choline); (iv)
transcytosis of macromolecules by receptor-mediated or
adsorptive-mediated mechanism (transport of transferrins,
lipoproteins, glycosylated proteins, IgG, insulin, leptin, tumor
necrosis factor-alpha (TNF-𝛼), EGF, LIF, cationised albumin,
cell penetrating peptides); and (v) mononuclear leukocyte
migration [22, 23]. In this review, particular attention will be
devoted to ABC transporters with regard to chronic pain and
BBB, as the majority of the analgesics are substrates for these
transporters, especially for P-gp transporter [24–28].
The endothelial cells of capillary vessels play a major
role in BBB physiology. The flattened cells present a luminal
and an abluminal surface, separated by a 300–500 nm thick
cytoplasm in human brain microvessels [29]. The tight
junctions (TJs) connecting adjacent cells represent the most
significant BBB structure and serve a dual purpose. On
one hand, by sealing the intercellular space, they control
the paracellular transport pathway (“gate function”). On the
other hand, they effectively subdivide the membrane into
two distinct functional domains (“fence function”) [30]. The
endothelial cell polarization arises in particular from the
differential expression of specific transporter proteins on
Mediators of Inflammation 3
either surface. The TJ-associated membrane proteins com-
prise occludin, tricellulin (also called marvelD2), cingulin,
claudins (CL-1, CL-3, CL-5), junction-associated molecules
of the immunoglobulin superfamily (JAMs), zona occludens
proteins (ZO-1, ZO-2, ZO-3), 7H6, and AF-6 [7, 31, 32].
Signaling pathways involved in TJs regulation include G-
proteins, serine-, threonine- and tyrosine-kinases, extra-
and intracellular calcium levels, cAMP levels, proteases, and
cytokines, and all these pathways share the modulation of
cytoskeletal elements and the connection of TJs’ transmem-
brane molecules to the cytoskeleton [31].
In pathological states, such as neurodegenerative diseases
(including stroke, multiple sclerosis, rheumatoid arthritis,
and AIDS dementia) or neuroinflammation, BBB has an
uncontrolled and prolonged increase in permeability that
results in vasogenic edema and leakage of neurotoxic plasma
constituents [33].
2.3. ABC Transporters in BBB and BSCB. ABC transporters
represent the largest family of transmembrane proteins.
Upon binding ATP, these proteins translocate a wide variety
of substrates across extra- and intracellular membranes,
including metabolic products, lipids and sterols, and drugs
[34]. Tight junctions and ABC transporters expressed in
the brain and spinal cord endothelial capillaries represent
the major “guardians” of the transport through BBB/BSCB
endothelium. ABC transporters, such as P-gp, MRP 1–6, and
BCRP, are expressed in the barriers endothelium both in
humans and rodents [27].
It is presumed that only efflux transporters located on
the luminal (apical) side of the endothelium can restrict
drug uptake into the brain [25]. However, transport balance
(influx/efflux) is dramatically affected by pathological stres-
sors, such as status epilepticus and neurodegenerative diseases
[47–49], and has been suggested to be also partly modified in
inflammatory pain [26, 36, 37]. P-gp and BCRP expression
in the BBB is regulated during early inflammatory stages by
TNF-𝛼 and IL-1𝛽 [50].
Table 1 summarizes some of the links established so far
between ABC transporters in BBB/BSCB and chronic pain.
In conclusion, ABC transporters appear to play an impor-
tant role in inflammatory pain and in analgesia (opioids or
nonsteroidal anti-inflammatory drugs). Knocking out genes
encoding ABC transporters has consequences in inflamma-
tory pain or analgesic profile. For example, knocking out
the gene encoding for MRP4 increases inflammatory pain
threshold [45] and knocking out the gene encoding forMRP3
alters morphine pharmacokinetics [44]. Therefore, these
transporters, in particular P-gp, represent key molecules that
might contribute to BBB/BSCB permeabilization induced by
inflammation-like stimuli in various pain syndromes [26, 36,
37].
3. Cross Talk between NVU Partners in
Chronic Pain
In vitro and in vivo animal studies have confirmed NVU
cellular crosstalk in inflammation-induced hyperalgesia or
nerve injury models and results can be extrapolated to
chronic pain.
3.1. Glia-Neuron Interactions. Glia are significantly activated
in response to trauma, ischemia, and invading pathogens
by means of cytokine release (IL-1𝛽, TNF-𝛼) and may
contribute to the maintenance of chronic pain [51, 52]. In
addition to proinflammatory cytokine release at the periph-
eral site of injury, release also takes place in the CNS (spinal
cord, brainstem, and forebrain) [53–55]. Released cytokines
together with activated glia have been proved to influence
and modulate neurons in the trigeminal nucleus region in
a trigeminal model of inflammatory hyperalgesia [56]. On
the other hand, different signaling pathways mediate IL-1𝛽
actions in hippocampal neurons compared to astrocytes [57].
Glia activation within the CNS has been suggested to
maintain the pain sensation, even after the original injury
or inflammation has healed, and convert it into chronic pain
by altering neuronal excitability [58]. In a peripheral nerve
injury pain model, the inhibition of microglia after four
weeks fromnerve injury normalized the pain threshold,while
removing the inhibitor immediately restored pain-related
phenomena [52].
3.2. Microglia-Astrocytes Interactions. Both in vitro and in
vivo data provide clues on how the crosstalk between
microglia and astrocytes may play a role in chronic pain
maintenance [59–63]. The activation of microglia has been
shown to cause astrocytic activation, with a delay of about
4 days [54, 64]. Preventing microglial activation (and sub-
sequent astrocyte activation) inhibits hyperalgesia or allo-
dynia [59, 61]. Once the astrocytes are activated, inhibiting
microglia has no effect on pain [59, 60]. On the other hand,
brain astrocytes can be activated in response to peripheral
nerve injury without prior microglia differentiation [65].
A dialogue between microglia expressing IL-18 and astro-
cytes expressing its receptor (IL-18R) was suggested to be
important in tolerance to morphine analgesia, by means
of a P2X7R/IL-18/D-serine/N-methyl-D-aspartate receptor
(NMDAR)/PKC𝛾-mediated signaling pathway [62], but also
for tactile allodynia after nerve injury [66].
Increased monocyte chemotactic protein 3 (MCP-3,
known as CCL7) expression associated with IL-6-dependent
epigenetic modification at the MCP-3 promoter after nerve
injury, mostly in spinal astrocytes, may serve to facilitate
astrocyte-microglia interaction in the spinal cord and could
play a critical role in the neuropathic pain-like state [63].
Some studies suggest the importance of the triad neuron-
astrocyte-microglia in physiological and pathological inflam-
matory states [67].
3.3. Astrocyte-Endothelial Cell Interactions. Astroglial-endo-
thelial signalling is altered under pathological conditions,
such as infection, inflammation, stroke, or trauma, leading to
BBB opening [6]. The coupling between the abluminal capil-
lary cell membrane and the surrounding glial end-foot pro-
cesses is reduced in pathological conditions [68, 69]. Stimu-
lation of astrocytes, in coculture with brain endothelial cells,
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Table 1: ABC transporters presence in BBB and BSCB and their potential role in pain.
ABC transporter
(gene) BBB BSCB
Localization in
brain capillary
endothelium
Direction of
efflux/influx
Implications in pain/analgesics or anti-inflammatory
drugs versus ABC transporters
P-gp (ABCB1) Yes [24] Yes [35] Luminal [25] Blood [25]
There is an increased P-gp expression and dynamic
redistribution between membrane domains of
P-glycoprotein and caveolin-1 in peripheral
inflammatory pain [26, 36, 37]. P-gp is involved in pain
control with opioid analgesics [38]. Diclofenac is not
transported by P-gp [39].
MRP1 (ABCC1) Yes [24, 25, 40] Yes [40] Luminal [25]Abluminal [24]
Blood [25]
Brain [24]
The nonsteroidal anti-inflammatory drug
indomethacin, an efficient analgesic in some forms of
trigeminal autonomic cephalalgias (e.g., paroxysmal
hemicrania) [41], was proved to inhibit MRP1 function
and expression in cancer cell lines [42]. Most probably
indomethachin inhibits MRP1 in BBB.
Diclofenac, rofecoxib, and celecoxib are poor inhibitors
of MRP1 in HEK293 cells [43].
MRP2 (ABCC2) Yes [24, 27] Yes [35] Luminal [25] Blood [25] Diclofenac is not transported by MRP2 [39].
MRP3 (ABCC3) Yes [24] ? Abluminal [24] Brain [24]
Mice lacking MRP3 show altered morphine
pharmacokinetics and morphine-6-glucuronide
antinociception [44].
MRP4 (ABCC4) Yes [24, 27] ?
Luminal [25]
Abluminal
[24, 25]
Blood [25]
Brain [25]
Mice lacking MRP4 show increases in inflammatory
pain threshold compared to wild-type mice [45].
MRP4 acts as a prostaglandin efflux transporter and is
inhibited by nonsteroidal anti-inflammatory drugs
(e.g., indomethacin, indoprofen, ketoprofen, and
flurbiprofen) [43]. Diclofenac, rofecoxib, and celecoxib
are poor inhibitors of MRP4 [43].
MRP5 (ABCC5) Yes [24, 27] ? Luminal [25]Abluminal [24]
Blood [25]
Brain [24] ?
MRP6 (ABCC6) Yes [24, 27] Possible[46] Abluminal [24] Brain [24] ?
BCRP (ABCG2) Yes [24] Yes [35] Luminal[25] Blood [25]
Diclofenac, an analgesic mainly used against cancer-
associated chronic pain, is efficiently transported by
murine BCRP1 and moderately by human BCRP [39].
with 5-hydroxytryptamine (5-HT) generated a pronounced
increase in intracellular Ca2+ release in the presence of
inflammatory or pain-mediating activators, such as substance
P, calcitonin gene-related peptide (CGRP), lipopolysaccha-
ride (LPS), or leptin [70]. Mu-opioid agonists inhibit the
enhanced intracellular Ca2+ responses in inflammatory-
activated astrocytes cocultured with brain endothelial cells
[70]. Overexpression of endothelin-1 in astrocytes, but not
in endothelial cells, ameliorates inflammatory pain response
after formalin injection [71]. The role played in chronic pain
development by in vivo endothelial-astrocyte interaction at
the barrier has not been investigated yet.
3.4. Pericyte-Endothelial Cell Interactions. In vivo studies in
wild-typemice have shown that pericytes aremore numerous
in the brain than in the spinal cord [72]. Whereas brain
regions such as the neocortex, hippocampus, and caudate
nucleus showalmost uniformpresence of pericytes, the spinal
cord shows significantly nonuniform distributions along the
rostrocaudal extent, with the thoracic region being richer in
pericytes, but with no more than 70% of brain levels. This
reduced number of pericytes in the spinal cord correlates
with (i) a higher BSCB permeability, as probed by fluorescent
dextran and (ii) a diminished expression of tight junction
proteins ZO-1, occluding, and claudin-5. Compared to wild-
type mice, in 𝑃𝑑𝑔𝑓𝑟𝛽F7/F7 pericyte-deficient mice, pericytes
are reduced more in spinal cord capillaries, leading to BSCB
disruption to serum proteins. ZO-1 and occludin are also
reduced, and the accumulation inmotor neurons of cytotoxic
thrombin and fibrin leads to motor neuron loss [72]. In
another pericyte-deficient model, the 𝑃𝑑𝑔𝑓𝑏ret/ret mouse, an
increase in BBB permeability to water and to a range of
low- as well as high-molecular-mass tracers has been shown
[73]. Pericytes expressMRP1,MRP4, andMRP5 transporters,
which might imply a role played by these cells in regulating
xenobiotic transport through the BBB [74].
Abnormal interactions between pericytes and endothelial
cells have been implicated in a number of humanpathological
conditions, including tumor angiogenesis, diabetic microan-
giopathy, ectopic tissue calcification, and stroke and dementia
syndrome CADASIL [75]. In pathological conditions imply-
ing BBB damage, such as stroke, hypoxia, and traumatic brain
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injury, the pericytes migrate away from brain microvessels
wall and it seems to have an important role in neurovascular
unit repair [76–78].
Morphine potentiates endothelial-pericyte interaction
via platelet-derived growth factor-BB (PDGF-BB)/PDGF
receptor-𝛽 (PDGFR-𝛽) signaling and promotes tumor angio-
genesis, pericyte recruitment, and coverage of tumor vessels
[79]. The role of pericyte-endothelial cell interaction in
chronic pain development and the role of pericytes during
BBB disruption are still open topics.
4. BBB and BSCB in Chronic Pain: ‘‘To Be or
Not to Be’’ Permeabilized/Disrupted
4.1. Acute/Chronic Pain Induces Changes at the BBB and BSCB
Level. Does chronic pain cause BBB/BSCB permeabilization
or disruption? The variety and complexity of the clinical
conditions that involve chronic pain make a simple answer
impossible, and studies on animal models of acute/chronic
pain provide controversial responses to this hypothesis.
In the literature, the terms BBB “opening,” “leakage,”
and “breakdown” are often used interchangeably, but more
caution should be paid, when choosing between them [80]. A
distinction should be made between BBB “permeabilization”
and BBB “disruption” in experimental animalmodels. For the
purpose of this review, the term BBB permeabilization refers
to leukocytic recruitment associated with increased endothe-
lial permeability, with no tight junction opening or altered
efflux transport. As BBB “opening” or “permeabilization” is a
physiological phenomenon, it should be reserved to transient
processes [80]. On the other hand, we consider the BBB
“disrupted” if Evans blue (EB) or albumins are extravasated
into brain or spinal cord parenchyma. BBB “disruption” or
“breakdown” represents a long-term opening associated with
often-irreversible phenomena [80–82].
4.1.1. BSCB Permeabilization in Neuropathic Pain and Disrup-
tion in Chronic Pain Animal Models. Peripheral nerve injury
produced by either sciatic nerve constriction or selective
transection (peroneal and tibial nerve branches, but not sural
branch) causes a transient increase in BSCB permeability
in the lumbar and thoracic spinal cord, peaking about
24–48 h. after injury and returning to normal levels after
7 days, as assessed by EB dye or horseradish peroxidase
accumulation in the parenchyma [10]. BSCB permeability
was also increased 24 hours after electrical stimulation of the
sciatic nerve at intensity sufficient to activate C-fibers, but not
A-fibers, or after capsaicin application on the sciatic nerve
[10].
Partial sciatic nerve ligation in rats, a model of neuro-
pathic pain, triggers an increase of BSCB permeability in
the lumbar, but not in the thoracic, spinal cord to tracers
of different size (e.g., EB, sodium fluorescein), which was
prominent between day 3 and day 7, stayed significant for at
least 4 weeks after injury, and returned to normal levels after
2 months [11]. Contrasting results on BSCB permeability in
extralumbar spinal cord regions (e.g., thoracic) [10, 11] could
likely be attributed to EB protocol differences.
Plasma proteins (IgG and fibronectin) immunopositive
deposits in the ipsilateral side of the spinal parenchyma and
downregulation of tight junction proteins (ZO-1, occludin-
1, and caveolin-1) in isolated microvessels of the spinal cord
were found 3 days after injury [11]. BSCB permeabilization
occurs independently of the activation of resident microglial
cells, EB extravasation being present while a microglial
inhibitor minocycline is infused intrathecally from day 0 to
day 7 [11]. Additionally, it was shown that the administration
in rats of high doses of IL-1𝛽 (intravenous) impairs BSCB
disruption, while TGF-𝛽1 and IL-10 (intrathecal) shut down
the openings in BSCB [11].
In a recent study of perispinal inflammation induced by
applying the toll-like receptor (TLR)-2 agonist zymosan to
the dorsal dural surface of the L1/L2 spinal cord, the lack of
BSCB permeabilization was inferred from the lack of serum
proteins in the spinal parenchyma 24 h after surgery [12].
No immunohistological evidence of T-cell or Mac-1-positive
macrophages crossing into the parenchyma was found, but
ATF-3 (a transcription factor that is also a sensitive indicator
of neuronal injury) expression was observed in the dorsal
horn of the same spinal cord segments after 1 day [12].
Thus, inflammatory signals are indeed transduced across
the BSCB at the site of the inflammatory stimulus, within
a 400–500𝜇m radius. Astrocyte activation and gliosis are
significantly increased in the superficial dorsal horn 1–7 days
after surgery, with a transient recovery after 14 days, while
resident microglia cells show a steady increase in staining
density within the superficial dorsal horn beginning 1 day
after surgery [12].
Neuropathic pain induced by L4 spinal nerve lesions in
animal models is accompanied by astrocyte activation and
albumin leakage, revealing BSCB disruptionmore prominent
in the gray matter of the lesioned side compared to the con-
tralateral in both dorsal and ventral horns [83]. Inflammatory
events and changes in astrocyte and microglia reactivity at
the spinal level in response to injury or disease are important
processes that can initiate pain hypersensitivity [84, 85].
Studies conducted in a T-cell-deficient Rag1-null adult mouse
have shown that T-cell infiltration and activation in the
dorsal horn of the spinal cord following peripheral nerve
injury contribute to the evolution of neuropathic pain-like
hypersensitivity [86]. Most likely, the T-cell infiltration into
the spinal cord is higher than normal in the nerve-injured
animals, a fact that may be correlated with an increase in
BSCB permeability.
BSCB permeabilization is a delayed event with respect
to the initial injury and has a transient character. Studies
addressing the role of the endothelium in BSCB disruption
have been carried out, but the inclusion of the NVU as a
whole is needed [87]. While the activation of glia may be
important for the development of chronic pain, it is still
unclear if the activation is required for BSCB disruption or
if the two phenomena are independent. Peripheral inflam-
mation or nerve injury in animal models induces astrocytes
and microglia activation in the spinal cord [52, 88–91], but
in these studies evidence regarding BSCB permeabilization is
not available. In this view, new approaches connecting glia
activation to BSCB opening would be very useful.
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4.1.2. BBBPermeabilization inAnimalModels of Inflammatory
Pain. Inflammation induced by an intraplantar injection of
𝜆-carrageenan into the rat hindpaw causes increased brain
uptake (in situ brain perfusion) of [14C]sucrose at 1, 3, 6 and
48 h after injection [92]. In the same study,Western blot anal-
ysis on isolated cerebral microvessels indicated a transitory
increase in ZO-1 expression (increase after 1–6 h, returned to
control after 12 h.) and a reduction in occludin expression
(after 1, 3, 6, 12, and 48 h) [92]. These expression patterns
indicate increased BBB permeability and suggest a link with
the development of inflammatory pain. In another study
devoted to inflammatory pain, [14C]sucrose in situ brain
uptake, [3H] in situ cerebral flow, and Western blot analysis
(occludin, ZO-1, CL-1, and actin expression) were performed
1 h after formalin injection, 3 h after 𝜆-carrageenan injection
and 3 days after complete Freund’s adjuvant (CFA) injection,
and BBB permeabilization was observed [93].
In a rat model of inflammatory pain (injection of CFA
into the plantar hindpaw), significant edema formation and
hyperalgesia were observed 72 h. after treatment, together
with significant increases in brain sucrose uptake. Expression
of the transmembrane TJ proteins occludin, claudin-3 and
-5, and junction adhesion molecule-1 (JAM-1) significantly
changed 24–72 h after CFA injection, as proved by Western
blotting [9] and confocal microscopy [94].
The induction of peripheral inflammatory pain through
the injection of 𝜆-carrageenan was associated with increased
BBB permeability in a study that showed, by means of SDS-
PAGE/Western blot analysis, a significant change in the
relative amounts of oligomeric, dimeric, and monomeric
occludin isoforms in BBB endothelial cells, presumably
promoted by the disruption of disulfide-bonded occludin
oligomeric assemblies [95].
Expression of organic anion-transporting polypeptide
1a4 (Oatp1a4) is upregulated after 3 h exposure to 𝜆-car-
rageenan; the upregulation is prevented by diclofenac, sug-
gesting the implication of acute/chronic inflammatory pain
[36]. This modulation of BBB permeability in inflamma-
tory pain appears to be controlled by the TGF-beta/activin
receptor-like kinase-5 (ALK5) signaling pathway [96]. 𝜆-
carrageenan-induced peripheral inflammatory pain gener-
ates increased [14C]sucrose and [3H]codeine in situ brain
uptake, and rats pretreated (10min before 𝜆-carrageenan
injection) with tempol, a pharmacological ROS scavenger,
have an attenuated radiotracers uptake [97]. In the same
study, other indirect pieces of evidence for BBB modulation
have been presented consisting in increase of the nitrosylated
proteins in isolated brain vessels extract.
In a 𝜆-carrageenan inflammatory pain model, unidi-
rectional permeability coefficients for several selected brain
regions (hypothalamus, cerebellum, midbrain, cerebrum,
hippocampus, brainstem, and thalamus) were calculated.
Three hours after 𝜆-carrageenan injection, the BBB resulted
in an increased permeability in cerebrum and brainstem;
diclofenac administration reversed this effect [98]. Western
blot analysis of occludin expression in the same brain regions,
however, did not reveal any significant changes [98]. In
conclusion, correlating occludin expression changes with
BBB “permeabilization” is problematic on the basis of the
available data.
Administration of EB, which readily binds to serum
albumins, is “classically” employed to assess BBB integrity,
since in normal conditions the dye should not be found in
the brain parenchyma [10]. However, in order to be revealed
by EB, BBB disruption must be of a substantial degree (e.g.,
ischemic stroke [99]), while inflammatory pain per se does
not constitute sufficient stimulus [100]. Inflammatory pain is
more likely related to BBB permeabilization, as suggested by
[
14C]sucrose transport through the BBB using in situ brain
perfusion [9].
Despite the valuable information contained in the above
described studies, there are several experimental pitfalls to
be considered. First, only indirect pieces of evidences are
available in support of the idea of BBB permeabilization in
inflammatory or chronic inflammatory pain. It is difficult to
assess BBB permeabilization based on changes in TJ protein
expression in an homogenate of isolated brain capillaries or to
expand results from in situ brain perfusion with radioactive
tracers to the BBB permeabilization. Another problem is
that relatively short experimental durations (such as 24–
72 h) are considered equivalent to a “chronic” pain state [9],
while similar experiments on BSCB permeabilization were
carried out over a significantly longer time scale (1 week–2
months) [10–12]. More consistent studies, based on in vivo
brain uptake of Evans blue or [14C]sucrose should be done
in order to prove BBB permeability changes. Alternative in
vivo methods, such as intravital microscopy [101] or nuclear
imaging of radioisotope-labeled leukocytes [72], are still
unexplored in the field of chronic pain. A regional brain
mapping of BBB permeabilization from the initial acute
pain induction to the late chronic pain phase would be of
significant use. In any case, clinical translation of the results
obtained with experimental inflammatory painmodels is still
far from accomplished.
Possible changes in BBB and/or BSCB permeability as a
result of acute and chronic pain are shown in Figure 1.
4.2. Chronic Pain Treatments and NVU. Two major classes
of analgesic drugs are currently in use for chronic pain
treatment: opioids and nonsteroid anti-inflammatory drugs
(NSAIDs). NSAIDs are used to treat chronic mild to moder-
ate pain, while opioids are powerful analgesic agents used to
treat moderate to severe chronic pain [102].
On the other hand, beside a wide range of adverse effects,
long-term clinical administration of opioids (e.g., morphine)
in chronic pain therapy is prevented by tolerance and depen-
dence [102]. A classical dogma holds that agonist-induced 𝜇-
opioid receptor internalization contributes directly to func-
tional receptor desensitization and opioid tolerance [103].
By contrast, other studies suggest that opioid receptor inter-
nalization can reduce opioid tolerance in vivo (reviewed
by [103]). Beside neurons, other NVU players (e.g., glial
cells, pericytes) have been considered to contribute to opioid
tolerance development [62, 79, 104]. Endothelial cell lining
represents the first “defence” to be crossed by opioids before
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interacting with CNS cells and therefore efflux alterations at
this level are crucial in opioid tolerance.
In the 𝜆-carrageenan rat model, acute inflammatory pain
generates an increased functional expression and trafficking
tomembrane domains of endothelial efflux transporters (e.g.,
P-gp) in the BBB microvasculature [26, 37]. On the other
hand, the same rats treated with morphine show reduced
brain uptake of the drug due to increased P-gp activity [26].
Coadministration of cyclosporine A (P-gp inhibitor) with
morphine in rats increased morphine transport through the
BBB in a dose-dependent manner [26]. In the clinical prac-
tice, reducing tolerance to morphine by co-administration
with cyclosporine A is unfeasible due to severe side effects
(nephro- and neurotoxicity) [105, 106].
Chronic morphine treatment induced an increase in the
expression of interleukin (IL)-18 by microglia, IL-18 receptor
(IL-18R) by astrocytes, and protein kinase C𝛾 (PKC𝛾) by
neurons in the spinal dorsal horn. The results were inter-
preted by the authors as signs of a complex glia-neuron
dialogue in the process of developing tolerance to morphine
[62]. Morphine also potentiates endothelial-pericyte inter-
action via PDGF-BB/PDGFR-𝛽 signaling [79]. Morphine
upregulates sphingolipid ceramide (in spinal astrocytes and
microglia, but not in neurons) and spinal sphingosine-1-
phosphate [104]. In turn, sphingosine-1-phosphatemodulates
spinal glial function, increasing the production of glial-
related proinflammatory cytokines, in particular TNF-𝛼, IL-
1𝛽, and IL6 [104].
Another major line of chronic pain treatment is rep-
resented by nonopioid analgesics such as NSAIDs. These
drugs have several side effects, the most important being
the risk of serious upper gastrointestinal complications,
including bleeding, ulcers, and perforation [102]. NSAIDs
act on the descending pain control system, which includes
the periaqueductal gray matter and rostral ventromedial
region of the medulla, which are also targets for endogenous
opioids. Therefore, repeated administration of NSAIDs (e.g.,
metamizol, lysine-acetylsalicylate, analgine, ketorolac, and
xefocam) to rats induces tolerance to themselves and cross-
tolerance to opioids [107, 108].
Studies suggest that NSAIDs interact in several differ-
ent ways with the brain endothelium, either by reducing
edema and BBB/BSCB permeabilization [109, 110] or by
inhibiting endothelial ABC transporters (e.g., MRP1, MRP4)
[42, 43]. Diclofenac attenuates edema and hyperalgesia
induced by 𝜆-carrageenan in the cerebral and brainstem
regions [98]. Indomethacin, an inhibitor of cyclooxyge-
nase (COX)-1 and COX-2, reduces BBB damage induced
by intracerebral injection of TNF-𝛼 [109]. Pretreatment
with p-chlorophenylalanine, indomethacin, ibuprofen, and
nimodipine of rats with spinal cord injury, reduced edema
formation, BSCB permeabilization, and blood flow [110].
Indomethacin was shown to be an inhibitor of MRP1 func-
tion [42] and indomethacin, indoprofen, ketoprofen, and
flurbiprofen inhibit MRP4 [43]. Diclofenac is transported by
BCRP, but not by P-gp [39].
5. Comorbidities of Chronic Pain with
Neuroinflammatory and Neurodegenerative
Diseases: Role of the Neurovascular Unit
Chronic pain has an extensive palette of comorbidities,
but only neuroinflammatory and neurodegenerative dis-
eases with known alterations of the NVU are here dis-
cussed (Figure 2). High prevalence of chronic pain can be
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observed in all these CNS pathologies. BBB/BSCB alter-
ations in epilepsy, Alzheimer’s disease, Parkinson’s disease,
multiple sclerosis, and amyotrophic lateral sclerosis will be
briefly described, with regard to chronic pain syndromes.
Understanding the exact role played by each pathology in
permeabilizing/disrupting brain and spinal cord capillaries’
endothelium is a crucial step in finding better therapeutic
solutions.
5.1. Epilepsy and Chronic Pain. Epilepsy is a set of chronic
neurological disorders characterized by abnormal, excessive,
or hypersynchronous neuronal activity in the brain. The
Epilepsy Comorbidities and Health (EPIC) Survey recently
performed in the United States indicated that epilepsy is
comorbid with several pain disorders, such as migraine,
chronic pain, fibromyalgia, and neuropathic pain [111]. Addi-
tionally, the EPIC study indicated that chronic pain is
prevalent in 25.4% of epileptic versus 17.7% of nonepileptic
survey responders [111]. Chronic pain and fibromyalgia may
be related to physical inactivity, which is more prevalent
among adults with a history of epilepsy than among those
without epilepsy [112].
The recent IASP taxonomy includes epilepsy in the list of
generalized syndromes of chronic pain and includes chronic
paroxysmal hemicrania—remitting form and hemicrania
continua in the list of the chronic pain conditions [1]. Epilepsy
and ictal epileptic headache share several pathophysiological
mechanisms, such as (i) EEG abnormalities—lateralized or
generalized, ipsilateral or contralateral, with focal theta activ-
ity or generalized spike-waves, and brief or longer-lasting
episodes and (ii) headache and EEG anomalies resolve within
minutes of i.v. antiepileptic medication administration [113].
The overlap between migraine and epilepsy may be partial
or complete, not necessarily synchronous (preictal, ictal, or
postictal), and in some cases the headache may represent the
only ictal phenomenon [113]. In pediatrics studies, 3.1% of
the patients suffered from idiopathic headache and idiopathic
or cryptogenic epilepsy or unprovoked seizures [114]. The
same study showed a strong association between migraine
and epilepsy: in migraineurs the risk of epilepsy was 3.2
times higher when compared to tension-type headache,
and children with epilepsy had a 4.5-fold increased risk
of developing migraine than tension-type headache [114].
Postictal headache occurred in 41% of temporal lobe epilepsy
patients, 40% of frontal lobe epilepsy patients, and 59% of
occipital lobe epilepsy patients [115].
Several mechanisms have been proposed to explain
comorbidity of epilepsy and chronic pain (such as that
characterizing migraine), such as (i) the essential role of
glutamate as a mediator of the hyperexcitability in both focal
seizures and migraine, considering that seizure generation
and spread are mediated by synaptically released glutamate
acting on AMPA receptors, while triggering of cortical
spreading depression depends on NMDA receptors and
spread does not require synaptic transmission; (ii) mutations
in genes for the membrane ion transport proteins CACNA1A
(P/Q-type voltage-gated calcium channel), ATP1A2 (Na+-K+
ATPase), and SCN1A (voltage-gated sodium channel) [116].
Another important mechanism implied in chronic pain
comorbidity with epilepsy is NVU activation. In this respect,
brain endothelium seems to play an important role.
BBB disruption induces epileptiform activity [117–122].
We have previously shown that BBB leakage is induced by
acute seizure activity but prevented by blockade of leukocyte-
vascular adhesion, either with blocking antibodies or by
genetically interfering with P-selectin glycoprotein ligand-1
(PSGL-1) function in mice [123]. Endothelial proinflamma-
tory chemokines induce complex signal transduction path-
ways leading to integrin activation and controlling leukocyte
recruitment, and therefore play a critical role in epileptogen-
esis [124, 125].
ABC transporters in the BBB are also affected in epilepsy.
Shortly after status epilepticus, MRP1, MRP2, and BCRP are
upregulated in astrocytes within several limbic structures,
including hippocampus [47]. In chronic epileptic rats, these
proteins are overexpressed in the parahippocampal cortex,
specifically in blood vessels and astrocytes surrounding these
vessels [47].
Whether transient BBB opening occurs during migraine
attacks is controversial. Some magnetic resonance imaging
studies have reported negative results [126, 127] while others
have found indications of BBB leakage [128]. In migraine,
indirect evidence for BBB permeabilization is provided by
increased circulating levels of matrix metalloproteinases
(MMPs) 2 [129] and 9 [130] that have been attributed to
MMPs release from the extracellular matrix of the neurovas-
cular unit.
5.2. Alzheimer’s Disease and Chronic Pain. Alzheimer’s dis-
ease (AD) is the most common cause of dementia. It is a
neurodegenerative disorder characterized by synaptic and
neuronal loss, by the accumulation in the extracellularmatrix
of beta-amyloid deposits, and by the presence of abnormal
aggregates of microtubule-associated proteins, the so-called
neurofibrillary tangles, in neuronal cell bodies.
Prevalence of pain in AD was estimated at 57% of
all patients [131], although such assessment is complicated
by two factors. First, pain processing may be altered in
dementias [132, 133] including AD [134]. Second, the primary
method for pain assessment is patient reporting [135], but
pain affects cognitive function [136, 137] and cognitive func-
tion in turn affects pain [133], which makes pain assessment
in AD very difficult.
Astrocytes tend to localize around fibrillar amyloid
plaques, suggesting that A𝛽 deposition is a potent trigger
of astroglial activation in the AD brain [138]. Additionally,
an increase in the number of IL-1 immunoreactive microglia
associated with AD plaques has been shown [139]. A variety
of biomarkers for microglial activation in AD have been pro-
posed, such as chitotriosidase, CCL18 (pulmonary activation-
regulated chemokine; PARC), YKL-40, CCL2 (monocyte
chemoattractant protein 1; MCP-1), CD14, and neopterin
[140].
Immunohistochemistry on postmortem human brains
affected by AD or vascular dementia indicated an increased
expression of CL-2, Cl-5, and CL-11 in neurons and of CL-2
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and CL-11 in astrocytes and oligodendrocytes [141]. There is
a strong relationship between neurodegeneration, cognitive
decline, and BBB disruption in AD [142]. It was suggested
that during neurodegeneration the receptor for advanced
glycation end products (RAGE), which mediates transfer of
amyloid-𝛽 to the brain through the endothelial cells, can be
upregulated [143]. In AD transgenic mice, BBB alteration was
proven to precede accumulation of senile plaques [144].
Neuroinflammation represents a crucial part in the
pathogenesis of AD and other neurodegenerative dis-
eases [145]. Inflammatory mediators, such as IL-1𝛽, IL-6,
TNF-𝛼, IL-8, transforming growth factor-𝛽 (TGF-𝛽), and
macrophage inflammatory protein-1𝛼 (MIP-1𝛼), are upregu-
lated in AD [146].
5.3. Parkinson’s Disease andChronic Pain. Parkinson’s disease
(PD) is a degenerative disorder of the CNS, mainly charac-
terized by loss of dopamine-generating cells in the substantia
nigra. Prevalence of pain (musculoskeletal pain, neuritic or
radicular pain, dystonia-associated pain, primary or central
pain, and akathitic discomfort) in PD is estimated around 40–
60% [147, 148]. See [149] for a comprehensive review of pain
in PD.
Impairment of BBB function has been implicated in the
pathogenesis of PD. Accumulation of verapamil (normally
extruded from the brain by P-gp) in the brain of PD
patients proves a dysfunction of BBB [150]. Injection of
dopamine neurotoxin 6-hydroxydopamine (6OHDA, which
produces Parkinson’s-like dopaminergic neuron lesions) into
the striatum of rats induced FITC-labeled albumin leakage
in areas of the brain that are not protected by the BBB
(e.g., the hypothalamus around the third ventricle and area
postrema along the floor of the fourth ventricle) but no
leakage inBBB-protected areas (e.g., ipsilateral parietal cortex
or hippocampus, or into contralateral structures) [151]. The
presence of neuroinflammatory markers, such as activated
microglia or astrocytes, is also an important feature of PD
[152]. Microglia activation and upregulation of inflammatory
mediators can be induced by 𝛼-synuclein and contributes
to PD pathogenesis [153]. On the other hand, astrocyte
activation in PD is still under debate [152, 154–158]. In a
recent study performed on aged c-rel−/− mice developing
PD-like degeneration of substantia nigra pars compacta, we
observed a marked microglia activation in the substantia
nigra pars compacta and striatum, but no GFAP-positive
astrocyte activation [159].
5.4. Multiple Sclerosis and Chronic Pain. Multiple sclero-
sis (MS) is a chronic inflammatory disease of the CNS,
which leads to demyelination, neurodegeneration, perivascu-
lar edema, and inflammatory infiltrates [160]. Prevalence of
pain in MS is estimated around 50–86% [161, 162]. A recent
classification based on pathophysiological mechanisms and
response to treatment identified nine types of MS-related
pain: trigeminal neuralgia and Lhermitte’s phenomenon
(paroxysmal neuropathic pain due to ectopic impulse gen-
eration along primary afferents), ongoing extremity pain
(deafferentation pain secondary to lesion in the spinothalam-
ocortical pathways), painful tonic spasms and spasticity pain
(mixed pains secondary to lesions in the central motor path-
ways but mediated by muscle nociceptors), pain associated
with optic neuritis (nerve trunk pain originating from nervi
nervorum), musculoskeletal pains (nociceptive pain arising
from postural abnormalities secondary to motor disorders),
migraine (nociceptive pain favored by predisposing factors or
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secondary tomidbrain lesions), and treatment-induced pains
[163].
BBB disruption is an early event in the progression
of MS, as proved by magnetic resonance imaging studies
[164, 165]. Diapedesis of monocytes and subsequent traf-
ficking of monocyte-derived macrophages into the brain
are key mediators of demyelination and axonal damage in
MS. Endothelin 1 (ET-1), its type B receptor (ET(B)) and
endothelin-converting enzyme-1 (ECE-1) are mediators for
monocyte diapedesis through the human BBB and play
a key role in demyelination and axonal damage in MS
[166]. In experimental models of MS, such as experimental
autoimmune encephalomyelitis (EAE), BBB disruption is
induced by T-cells in conjunction with antigen-presenting
dendritic cells [167, 168], and monocytes [169]. MS lesions
are often found in proximity to blood vessels [170], associated
with loss of occludin and ZO-1 in the microvasculature [171–
173]. Leukocyte extravasation through BBB is mediated by
cytokines: TNF-𝛼, IL-1B, and interferon-𝛾 [174]. Infiltration
of inflammatory cells are localized perivascularly, but can also
be located in the CNS parenchyma. In acute inflammatory
lesions, CD4+ and CD8+ T cells and B cells infiltrate the
lesion site. Lesions at later MS stages show an abundance of
macrophages with internalized myelin degradation products
and reactive proliferating astrocytes [175]. Sodium channels
contribute to activation of microglia and macrophages in
EAE [176].
MS is also characterized by significant changes in the
composition and dynamics of the BSCB [177]. CD3-positive
T-cells accumulate within the dorsal horn in mice with EAE,
early in the disease course when cold and tactile allodynia are
observed [178]. BSCB disruption is greatest at disease onset,
followed by inflammation and demyelination, indicating
that increased BSCB permeability precedes the destructive
inflammatory process [177]. A recent study showed that
autoreactive T cells access CNS via the fifth lumbar spinal
cord in EAE mouse model [179].
In an EAE model, a recent study suggested a signalling
role for Wnt (a family of secreted signaling proteins) in
MS-associated chronic pain pathogenesis, although only
neurons and glial cells were examined [180]. On the other
hand, Wnt signaling contributes to brain angiogenesis, BBB
formation, influences vascular sprouting, remodelling, and
arteriovenous specification bymodulating theNotch pathway
[181]. Therefore, further studies on Wnt signalling in brain
microvasculature could bring new insights in to MS-related
pain syndromes.
5.5. Amyotrophic Lateral Sclerosis and Chronic Pain. Amy-
otrophic lateral sclerosis (ALS) is a chronic, progressive, and
ultimately fatal neurodegenerative disease of motor neurons
in the brain and spinal cord [182]. Prevalence of chronic
pain (especially located at the arms level) in ALS is estimated
around 15–20% [183, 184].
Increased permeability of the BSCB has been implicated
in the pathogenesis of ALS [185]. Studies conducted in the
ALS mouse model SOD1-G93A have shown BBB and BSCB
disruption [186, 187], in areas of motor neuron degeneration
(early and late ALS stages) [186] and capillary rupture
in brainstem (early symptomatic ALS stage) [186]. Some
studies indicate reduction in tight junction proteins (ZO-
1, occluding, and claudin-5) before motor neuron loss, in
presymptomatic ALS stages [188], while other data point out
the reduction in tight junctions proteins (ZO-1 and occludin)
and basement membrane protein agrin in symptomatic ALS
stages [187].Therefore, it is still controversial if the BBB/BSCB
disruption is the cause or the consequence of ALS devel-
opment. In SOD1-G93A mice, an increase was detected in
mRNA and protein levels for P-gp and BCRP at the level of
capillary endothelium in several regions, such as whole spinal
cord, cerebral cortex, and cerebellum [189]. Additionally, the
transport activity of P-gp and BCRP increased with ALS
progression in spinal cord and cerebral cortex capillaries
[189].
T lymphocytes are able to cross into the brain and
spinal cord parenchyma, where they interact with resident
microglia, inducing them to adopt either an M1 (cyto-
toxic) or M2 (protective) phenotype, depending on ALS
stage [190]. Clinical studies evidenced perivascular and
intraparenchymal CD4+ T-lymphocytes in the proximity
of degenerating corticospinal tracts and ventral horns in
two-thirds of ALS patients [191]. CD4+ T-lymphocytes slow
disease progression, modify the microglial phenotypes, and
extend survival [192, 193]. A potential mechanism behind the
longer life expectancy may be mediated by the augmented
secretion of IL-4 from mutant Cu2+/Zn2+ superoxide dis-
mutase regulatory T lymphocytes that directly suppressed
the toxic properties of microglia [193]. It was suggested that
CD4+CD25HighFoxP3+ regulatory T lymphocytes (Tregs) are
neuroprotective and slow ALS progression [194].
6. Potential Strategies Targeting BBB or
BSCB for Chronic Pain Relief
The molecular mechanisms of BBB/BSCB permeabilization
due to chronic pain have yet to be clarified. Nevertheless,
the barriers represent promising targets in designing new
therapeutic strategies for chronic pain. Several approaches
tested in preclinical and clinical studies, such as the use of
Rho-kinase inhibitors, antiepileptic compounds, and statins,
might turn out to be viable solutions in the future.
6.1. Rho-Kinase Inhibitor. Rho kinase (ROCK) is in- volved
in various physiological functions, including cell mo-
tility, vasoconstriction, and neurite extension. ROCK
inhibition reduces tissue-type plasminogen activator (t-
PA)/plasminogen-mediated increase in permeability of in
vitro models of the BBB [195]. Fasudil, a specific ROCK
inhibitor, partly alleviates EAE-dependent damage by
decreasing BBB and BSCB permeability [196]. In preclinical
models of pain, fasudil (30mg/kg) significantly attenuated
mechanical allodynia in spinal-nerve ligation, chronic
constriction injury, capsaicin-induced secondarymechanical
hypersensitivity, sodium iodoacetate-induced pain, and
capsaicin-induced acute flinching behaviors, but failed
to attenuate or had only modest effects on inflammatory
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thermal hyperalgesia following carrageenan injection
and mechanical allodynia following complete Freund’s
Adjuvant injection [197]. Fasudil also proved to be efficient
in adjuvant-induced arthritis model (inflammatory arthritis
model) and a monoiodoacetate-induced arthritis model
(noninflammatory arthritis model) [198].
6.2. Antiepileptic Drugs. It is difficult to consider currently
market-available antiepileptic drugs (AEDs) as an alternative
for classical analgesics because of their side effects, potential
drug interactions, and unsatisfactory efficacy (epilepsy resis-
tance). Between 1990 and 2012, 16 new AEDs were approved,
most of themdeveloped usingmechanism-unbiased anticon-
vulsant animal models [199]. In order to be attractive for the
pharmaceutical industry, the future design of newAEDsmust
also include a potential in nonepileptic CNS disorders, such
as bipolar disorder and neuropathic pain [199]. Resistance to
AEDs is encountered in more than 40% of epileptic patients
[25], probably due to upregulation of the efflux transporters
in brain capillary endothelium [200].
Only three AEDs are currently approved by the Food
and Drug Administration (FDA) and European Medicines
Agency (EMA) for the treatment of neuropathic pain:
carbamazepine (CBZ), gabapentin (GBP), and pregabalin
(PGB), all of them considered first-line treatment options
for several neuropathic pain conditions (reviewed by [199]).
Randomized clinical trials in spinal cord injury-related pain
indicate gabapentin and pregabalin as powerful analgesics
[201]. Cochrane Library reports based on extended clinical
trials indicate GBP, PGB, and lacosamide, but not valproic
acid, to be efficient against neuropathic pain or fibromyalgia
[202–205].
Levetiracetam (LEV)may constitute a novel approach for
BBB protection [206]. Clinical studies have evidenced the
effects of levetiracetam (LEV) in various pain conditions,
such as postmastectomy pain syndrome, trigeminal neural-
gia, chronic general or central pain in MS, lumbar radicu-
lopathy, chronic daily headache, polyneuropathy, and central
poststroke pain [207–212]. In a rat model of hypothermia-
induced cortical dysplasia, LEV and topiramate were found
to protect the BBB [212]. However, a recent clinical trial
failed to reveal significant effects of LEV against spinal cord
injury-related pain [213]. Despite LEV’s protective properties
on the BBB, clinical efficacy against chronic pain is still
controversial.
6.3. Statins. Beside the well-known efficacy of statins
(inhibitors of HMGCoA (3-hydroxy-3-methyl-glutaryl-
coenzyme A) reductase) in lowering plasma cholesterol
levels, these compounds show a large palette of pleiotropic
effects. Statins can improve endothelial function (thereby
regulating the BBB permeability), decrease the oxidative
stress and inflammation, and generally have a beneficial
effect on the immune system, central nervous system, and
bone [214]. Some of these effects point out statins as good
candidates for chronic pain treatment. In vivo preclinical
tests showed that Atorvastatin (a lipophilic statin) restored
the BBB permeability in mice fed with saturated fatty acids
(which compromised BBB integrity) [215]. In primary
human skeletal muscle myoblast cells, atorvastatin and
rosuvastatin proved to be substrates for MRP1, MRP4, and
MRP5 transporters [216].
An analgesic effect was revealed by hot-plate test for some
statins [217]. Preclinical tests have been performed to evaluate
statin efficacy in neuropathic pain. Daily administration of
statin for two weeks completely prevented the development
of mechanical allodynia and thermal hyperalgesia in a nerve
injury model [218]. Such approaches provide promising
results for considering statins as a possible future generation
of drugs against chronic pain, especially for patients with
dislipidemy.
7. Future Perspectives
General mechanisms of chronic pain onset, development,
and maintenance still await clarification, and the partic-
ular relationship between chronic pain and NVU func-
tion is an especially complex issue. Whether permeabiliza-
tion/disruption of the endothelial barrier in brain or spinal
cord could be a cause and/or a consequence of chronic pain is
an open topic. Clearly, a better knowledge of the neurovascu-
lar unit contribution to chronic pain physiopathology would
be highly beneficial in the clinical practice, especially in view
of pharmacological targeting of the NVU.
The use of currently available analgesics (opioids and
NSAIDs, in particular) in chronic pain is limited by their side
effects and by the induction of tolerance and/or dependence.
In this review, we have described some aspects of the
neurobiological mechanisms of chronic pain, with partic-
ular emphasis on NVU players’ interactions, also in view
of present and future treatments. Future strategies against
chronic pain should take into account the essential role
played by the neurovascular unit in the efficacy of analgesics
in an effort to overcome the already-known problems.
As many neurodegenerative/neuroinflammatory
pathologies are comorbid with chronic pain in a significant
number of patients, the identification of dual-target
therapeutic strategies should be considered a priority.
With the NVU as an increasingly relevant target for the
treatment of chronic pain, development of immunologically
based strategies for preventing BBB and/or BSCB permeabi-
lization or disruption would also represent an opportunity.
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